Pharmacogenetics and Ethnicity: Relevance for Clinical Implementation, Clinical Trials, Pharmacovigilance and Drug Regulation in Latin America

References

• Leonardi M , UstunTB . The global burden of epilepsy . Epilepsia43 ( 6 ), 21 – 25 ( 2002 ).
   PubMedGoogle Scholar
• Fricke-Galindo I , Martínez-JuárezIE , Monroy-JaramilloNet al. HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients . Pharmacogenomics15 ( 15 ), 1881 – 1891 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ortega-Vázquez A , DoradoP , Fricke-GalindoIet al. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy . Pharmacogenomics J.16 ( 3 ), 286 – 292 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Céspedes-Garro C , Jiménez-ArceG , NaranjoMEGet al. Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans . Rev. Biol. Trop.62 ( 4 ), 1659 – 1671 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Céspedes-Garro C , Rodrigues-SoaresF , Jimeénez-ArceGet al. Relevance of the ancestry for the variability of the drug-metabolizing enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population . Rev. Biol. Trop.64 ( 3 ), ( 2016 ) ( In press ).
   PubMed Web of Science ®Google Scholar
• de Andres F , TeránS , BoveraMet al. Multiplex phenotyping for systems medicine: a one-point optimized practical sampling strategy for simultaneous estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 activities using a cocktail approach . OMICS20 ( 2 ), 88 – 96 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• de Andres F , TeranS , HernandezFet al. To genotype or phenotype for personalized medicine? CYP450 drug metabolizing enzyme genotype–phenotype concordance and discordance in the Ecuadorian population . OMICS ( 2016 ) ( In Press ).
   Web of Science ®Google Scholar
• Kehdy FS , GouveiaMH , MachadoMet al. Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations . Proc. Natl Acad. Sci. USA112 ( 28 ), 8696 – 8701 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• de Andrés F , Sosa-MacíasM , Lazalde-RamosBPet al. Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail . Drug Metabol. Drug Interact.28 ( 3 ), 135 – 146 ( 2013 ).
   PubMedGoogle Scholar
• de Andrés F , Sosa-MacíasM , LlerenaA . A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity . Bioanalysis6 ( 5 ), 683 – 696 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Naranjo ME , de AndrésF , DelgadoAet al. High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies . Pharmacogenomics J. doi:10.1038/tpj.2016.47 ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Moya G , DoradoP , FerreiroVet al. High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina . Pharmacogenomics J. doi:10.1038/tpj.2016.27 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Perez-Paramo YX , Hernandez-CabreraF , DoradoPet al. Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem . Pharmacogenomics16 ( 7 ), 703 – 712 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• López-López M , Peñas-LledóE , DoradoPet al. CYP2D6 genetic polymorphisms in southern Mexican Mayan Lacandones and Mestizos from Chiapas . Pharmacogenomics15 ( 15 ), 1859 – 1865 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lazalde-Ramos BP , Martínez-Fierro MdeL , Galaviz-HernándezCet al. CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico . Pharmacogenomics15 ( 3 ), 339 – 348 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dorado P , HerasN , MachínEet al. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population . Eur. J. Clin. Pharmacol.68 ( 5 ), 637 – 644 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Llerena A , DoradoP , RamírezRet al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans . Pharmacogenomics J.12 ( 2 ), 176 – 183 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Llerena A , AlvarezM , DoradoPet al. Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain . Pharmacogenomics J.14 ( 3 ), 229 – 234 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dorado P , Sosa-MaciasMG , Peñas-LledóEMet al. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards . Pharmacogenomics J.11 ( 2 ), 108 – 112 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sosa-Macías M , Lazalde-RamosBP , Galaviz-HernándezCet al. Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from northwest Mexico . Pharmacogenomics J.13 ( 6 ), 567 – 572 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dorado P , BeltránLJ , MachínEet al. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender . Pharmacogenomics13 ( 15 ), 1711 – 1717 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• López M , DoradoP , OrtegaAet al. Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations . Mol. Biol. Rep.40 ( 4 ), 3187 – 3192 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sosa-Macías M , LlerenaA . Cytochrome P450 genetic polymorphisms of Mexican indigenous populations . Drug Metabol. Drug Interact.28 ( 4 ), 193 – 208 ( 2013 ).
   PubMedGoogle Scholar
• Fricke-Galindo I , Jung-CookH , LLerenaAet al. Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics) . Drug Metab. Pers. Ther.31 ( 2 ), 61 – 81 ( 2016 ).
   PubMedGoogle Scholar
• Céspedes-Garro C , NaranjoME , RamírezRet al. Pharmacogenetics in Central American healthy volunteers: interethnic variability . Drug Metab. Pers. Ther.30 ( 1 ), 19 – 31 ( 2015 ).
   PubMedGoogle Scholar
• LLerena A , NaranjoME , Rodrigues-SoaresFet al. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations . Expert Opin. Drug Metab. Toxicol.10 ( 11 ), 1569 – 1583 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Céspedes-Garro C , Fricke-GalindoI , NaranjoMEet al. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes . Expert Opin. Drug Metab. Toxicol.11 ( 12 ), 1893 – 1905 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Fricke-Galindo I , Céspedes-GarroC , Rodrigues-SoaresFet al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations . Pharmacogenomics J.16 ( 2 ), 113 – 123 ( 2016 ).
   PubMed Web of Science ®Google Scholar